NASDAQ
3.22USD
+0.04 (+1.21%)
We have scored 10 news catalysts on Addex Therapeutics Ltd (ADXN) over the past 12 months. The biggest single-day move next to one of them came Sep 28, 2026, when ADXN closed −23.0%: “Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update”. Coverage across the window leans positive (average ticker sentiment +0.32). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4M
P/E
—
EPS
—
Beta
1.96
52W range
2.56-11.97
Day range
2.97–3.25
Open
3.09
Prev close
3.18
Volume
4.4K
Avg volume
95.4K
Dividend
0.00
IPO
2020-02-12
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Addex Therapeutics Ltd — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ADXN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
